不确定潜能的克隆性造血与老年人静脉血栓栓塞发生率
基于社区动脉粥样硬化风险研究队列,纳入3980名无VTE或血液恶性肿瘤史的老年人,全外显子测序判定CHIP(变异等位基因频率≥2%)。中位随访7.1年,CHIP携带者VTE发生率为4.5%,非携带者为3.2%(HR 1.49,95%CI 1.02-2.17,P=.038),TET2突变与VTE风险显著相关(HR 2.25,95%CI 1.27-4.00,P=.006)。
要点
- CHIP携带者VTE风险轻度升高(HR 1.49,95%CI 1.02-2.17,P=.038)。
- TET2突变与VTE风险显著相关(HR 2.25,95%CI 1.27-4.00,P=.006)。
- CHIP与VTE的关联主要由TET2突变驱动。
核心结论
- 在老年人队列中,CHIP个体VTE风险轻度升高,主要由TET2突变驱动。
- 未来研究应探索驱动这些关联的机制并评估潜在治疗和预防策略。
研究设计与样本
- 社区动脉粥样硬化风险研究队列中无VTE或血液恶性肿瘤史的参与者。
- 采用外周血全外显子测序判定CHIP(变异等位基因频率≥2%)及常见基因特异性CHIP亚型(DNMT3A、TET2、ASXL1)。
- 主要结局为经专家病历审查裁定的症状性和无症状性肺栓塞及下肢深静脉血栓形成。
- 采用多变量Cox比例风险模型研究CHIP与VTE的关联。
- 共纳入3980名参与者,中位年龄75.0(71.0-79.0)岁,女性2359名(59.3%),男性1621名(40.7%),黑人890名(22.4%),白人3090名(77.6%),985名(24.7%)有CHIP。
主要发现
- 中位随访7.1年,CHIP携带者VTE发生44例(4.5%),非携带者96例(3.2%)(HR 1.49,95%CI 1.02-2.17,P=.038)。
- TET2突变与VTE风险显著相关(HR 2.25,95%CI 1.27-4.00,P=.006)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of cardiovascular diseases, but its association with venous thromboembolic events (VTE) is unclear. OBJECTIVES: We investigated the association between CHIP and incident VTE in older adults and evaluated whether risk varies by CHIP driver gene. METHODS: Participants from the community-based Atherosclerosis Risk in Communities Study without a history of VTE or hematologic malignancies were included. Whole-exome sequencing from peripheral blood was used to ascertain CHIP (variant allele frequency ≥ 2%) and common gene-specific CHIP subtypes (DNMT3A, TET2, and ASXL1). The primary outcome was incident VTE (adjudicated by experts from medical record review), defined as symptomatic and asymptomatic pulmonary embolism and lower extremity deep vein thrombosis. Multivariable Cox proportional hazard models were used to study the association between CHIP and VTE. RESULTS: Of 3980 participants included (median [25th-75th percentiles] age, 75.0 [71.0-79.0] years), 2359 (59.3%) were female, 1621 (40.7%) were male, 890 (22.4%) identified as Black, and 3090 (77.6%) identified as White; 985 (24.7%) had CHIP. Over a median 7.1-year follow-up, VTE occurred in 44 (4.5%) CHIP carriers vs 96 (3.2%) noncarriers (hazard ratio, 1.49; 95% CI, 1.02-2.17; P = .038). TET2 mutation was significantly associated with VTE risk (hazard ratio, 2.25; 95% CI, 1.27-4.00; P = .006). CONCLUSION: In this cohort study of older adults, we identified a modestly increased risk of VTE in individuals with CHIP, mainly driven by TET2 mutation. Future research should explore the mechanisms driving these associations and assess potential therapeutic and preventive strategies.
引用
- Saadatagah S, Kim RB, Sukumar S, et al. Clonal hematopoiesis of indeterminate potential and incidence of venous thromboembolism in older adults. J Thromb Haemost. 2025. PMID: 40252845. doi:10.1016/j.jtha.2025.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。